Vnitr Lek 2023, 69(6):397-405 | DOI: 10.36290/vnl.2023.078

What's new in rheumatology

Ladislav Šenolt, Mária Filková, Kristýna Bubová, Jakub Závada, Michal Tomčík, Jiří Vencovský, Šimon Tichý, Karel Pavelka
Revmatologický ústav, Praha
Revmatologická klinika, 1. LF UK, Praha

Rheumatology has experienced significant advances in recent years as a result of the emphasis on early diagnosis and the application of treat-to-target principles, as well as new immunopathogenetic findings and the availability of a wide range of biologic and targeted synthetic drugs. In this communication, we present new findings in the diagnosis and treatment of selected rheumatic diseases, specifically rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, systemic scleroderma, idiopathic inflammatory myopathies, systemic vasculitis, rheumatic polymyalgia and giant cell arteritis, and osteoarthritis. This communication aims to provide a summary of the latest findings and trends in the diagnosis and treatment of these rheumatic diseases, which have a major impact on the quality of life of patients.

Keywords: news, recommendations, targeted treatment, rheumatic diseases.

Accepted: September 21, 2023; Published: October 10, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šenolt L, Filková M, Bubová K, Závada J, Tomčík M, Vencovský J, et al.. What's new in rheumatology. Vnitr Lek. 2023;69(6):397-405. doi: 10.36290/vnl.2023.078.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Smolen JS, Landewe RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease­‑modifying antirheumatic drugs: 2022 update. Ann Rheum, DiS. 2023 Jan; 82(1):3-18. Go to original source... Go to PubMed...
    2. Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022 Jan 27; 386(4):316-326. Go to original source... Go to PubMed...
    3. Kristensen LE, Danese S, Yndestad A, et al Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum, DiS. 2023 Jul;82(7):901-910. Go to original source... Go to PubMed...
    4. van der Horst­‑Bruinsma IE, van Bentum RE, Verbraak FD, et al. Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C­‑VIEW study. Ther Adv Musculoskelet, DiS. 2021 Mar 29;13:1759720X211003803. Go to original source... Go to PubMed...
    5. Östör A, Van den Bosch F, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double­‑blind, phase 3 KEEPsAKE 2 trialAnnals of the Rheumatic Diseases. 2022;81:351-358. Go to original source... Go to PubMed...
    6. Ritchlin CT, Helliwell PS, Boehncke W, et al. Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic­‑naïve or TNFα inhibitor­‑experiencedRMD Open. 2021;7:e001457. Go to original source... Go to PubMed...
    7. Zucchi D, Silvagni E, Elefante E, et al. Systemic lupus erythematosus: one year in review 2023. Clin Exp Rheumatol. 2023 May;41(5):997-1008. Go to original source... Go to PubMed...
    8. Mackensen A, Müller F, Mougiakakos D, et al. Anti­‑CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022 Oct;28(10):2124-2132. Go to original source... Go to PubMed...
    9. Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685-99. Go to original source... Go to PubMed...
    10. Lepri G, Orlandi M, Di Battista M, et al. Systemic sclerosis: one year in review 2022. Clin Exp Rheumatol. 2022;40(10):1911-20.
    11. Lundberg IE, Fujimoto M, Vencovsky J, Aggarwal R, Holmqvist M, Christopher­‑Stine L, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021;7(1):86. Go to original source... Go to PubMed...
    12. Aggarwal R, Charles­‑Schoeman C, Schessl J, Bata­‑Csörgő Z, Dimachkie MM, Griger Z, et al. Trial of Intravenous Immune Globulin in Dermatomyositis. N Engl J Med. 2022;387(14):1264-1278. Go to original source... Go to PubMed...
    13. Stone JH, Spotswood H, Unizony SH, et al. New­‑onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension. Rheumatology (Oxford). 2022 Jul 6;61(7):2915-2922. Go to original source... Go to PubMed...
    14. Dejaco C, Ponte C, Monti S, et al. The provisional OMERACT ultrasonography score for giant cell arteritis. Ann Rheum, DiS. 2022 Dec 12:ard-2022-223367. Epub ahead of print.
    15. Nepal D, Putman M, Unizony S. Giant Cell Arteritis and Polymyalgia Rheumatica: Treatment Approaches and New Targets. Rheum Dis Clin North Am. 2023 Aug;49(3):505-521. Go to original source... Go to PubMed...
    16. Sánchez Álamo B, Moi L, Bajema I, et al. EUVAS. Long­‑term outcomes and prognostic factors for survival of patients with ANCA­‑associated vasculitis. Nephrol Dial Transplant. 2023 Jan 6:gfac320. doi: 10.1093/ndt/gfac320. Epub ahead of print. Go to original source... Go to PubMed...
    17. Pyo JY, Lee LE, Park YB, Lee SW. Comparison of the 2022 ACR/EULAR Classification Criteria for Antineutrophil Cytoplasmic Antibody­‑Associated Vasculitis with Previous Criteria. Yonsei Med J. 2023 Jan;64(1):11-17. Go to original source... Go to PubMed...
    18. Hellmich B, Sanchez­‑Alamo B, Schirmer JH, et al. EULAR recommendations for the management of ANCA­‑associated vasculitis: 2022 update. Ann Rheum, DiS. 2023 Mar 16:ard-2022-223764. doi: 10.1136/ard-2022-223764. Epub ahead of print. Go to original source... Go to PubMed...
    19. Gezer HH, Ostor A. What is new in pharmacological treatment for osteoarthritis? Best Pract Res Clin Rheumatol. 2023 Jun 9:101841. doi: 10.1016/j.berh.2023.101841. Epub ahead of print. PMID: 37302928. Go to original source... Go to PubMed...
    20. Dhillon J, Kraeutler MJ, Belk JW, et al. Effects of Running on the Development of Knee Osteoarthritis: An Updated Systematic Review at Short­‑Term Follow­‑up. Orthop J Sports Med. 2023 Mar 1;11(3):23259671231152900. Go to original source... Go to PubMed...
    21. Alimoradi N, Tahami M, Firouzabadi N, et al. Metformin attenuates symptoms of osteoarthritis: role of genetic diversity of Bcl2 and CXCL16 in OA. Arthritis Res Ther. 2023 Mar 7;25(1):35. Go to original source... Go to PubMed...
    22. Baker MC, Sheth K, Lu R, et al. Increased risk of osteoarthritis in patients with atopic disease. Ann Rheum, DiS. 2023 Mar 27:ard-2022-223640. doi: 10.1136/ard-2022-223640. Epub ahead of print. PMID: 36987654. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.